Point of Care Diagnostics Market: Growth, Size, Share, and Trends
Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029
USD 22.63 BN
MARKET SIZE, 2030
CAGR 8.5%
(2025-2030)
578
REPORT PAGES
787
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The point of care (POC) diagnostics market is expected to experience substantial growth, rising from USD 15.05 billion in 2024 to USD 22.63 billion by 2029, at a CAGR of 8.5% during the forecast period. This growth is largely driven by the increasing prevalence of chronic diseases such as diabetes and cardiovascular disorders, which demand continuous monitoring, early detection, and timely intervention. The rising need for fast, accurate, and convenient testing solutions has accelerated the adoption of POC diagnostics, particularly glucose monitoring devices, which allow patients and healthcare providers to track health status in real time and manage diseases proactively. Furthermore, supportive government policies, reimbursement initiatives, and growing investments in healthcare innovation are enhancing access to POC technologies, fostering technological advancements, and expanding their integration into clinical and home-care settings. Combined with increasing awareness among patients and clinicians about the benefits of decentralized testing, these factors are contributing to the overall growth and evolution of the POC diagnostics market.
KEY TAKEAWAYS
-
BY PRODUCTBased on product, the point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy and fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products. The glucose monitoring products segment dominates the market, primarily due to the growing global burden of diabetes. The increasing number of diabetic patients has led to a consistent need for convenient and accurate glucose monitoring devices for effective disease management. Continuous advancements in technology, along with greater accuracy, user-friendliness, and affordability, have further supported the widespread use of glucose monitoring products among both patients and healthcare professionals.
-
BY MODE OF PURCHASEThe point of care diagnostics market, based on mode of purchase, includes over-the-counter (OTC) testing products and prescription-based testing products. Prescription-based testing products dominate this segment due to their widespread use in clinical environments for the accurate diagnosis and management of chronic and infectious diseases. These tests are typically recommended by healthcare professionals to ensure precise detection and appropriate treatment planning. The growing incidence of conditions such as diabetes, cardiovascular diseases, and infections continues to drive the demand for prescription-based testing. Additionally, compliance with stringent clinical standards and regulatory requirements ensures high-quality outcomes, strengthening their adoption across healthcare systems.
-
BY TECHNOLOGYBased on technology, the point of care diagnostics market is segmented into immunoassays, molecular diagnostics, and biochemistry. Biochemistry technology holds a significant position in the market, as it is widely used for testing biochemical markers such as glucose, lipids, and electrolytes, which are essential for managing chronic conditions like diabetes, kidney disease, and cardiovascular disorders. Biochemistry-based point of care devices are preferred for their simplicity, rapid results, and cost-effectiveness, making them suitable for both clinical and home-care environments. Additionally, ongoing miniaturization and technological improvements have enhanced their accuracy and ease of use, further driving their adoption across various healthcare settings.
-
BY SAMPLECategorized by sample type, the point of care diagnostics market includes blood samples, urine samples, nasal and oropharyngeal swabs, and other sample types. Blood samples remain a primary choice due to their critical role in detecting a wide range of conditions, including diabetes, cardiovascular diseases, infectious diseases, and metabolic disorders. Blood-based tests are considered accurate, reliable, and capable of delivering rapid results, making them suitable for both clinical and near-patient settings. Technological advancements have further enhanced efficiency, allowing accurate testing with minimal sample volumes. With the continued rise of chronic and infectious diseases, the demand for rapid, convenient, and reliable blood-based diagnostics continues to drive the preference for this sample type.
-
BY END USERBased on end user, the point of care diagnostics market includes clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers and urgent care centers, home care settings and self-testing, and other end users. Home care settings and self-testing are increasingly becoming a key focus as patients seek convenience and comfort, allowing them to monitor their health without frequent visits to healthcare facilities. The rapid availability of results, especially for chronic conditions like diabetes, encourages the use of self-testing devices. Technological advancements have improved accuracy, ease of use, and affordability of home-based tests, enabling individuals with minimal training to perform them effectively. With the rise of chronic diseases and a growing emphasis on preventive care and self-management, home care settings and self-testing continue to drive demand in the point of care diagnostics market.
The point of care diagnostics market is projected to grow significantly in the coming years, driven by the increasing incidence of infectious and chronic diseases that require rapid and continuous monitoring. The growing prevalence of target conditions such as diabetes and cardiovascular disorders is fueling the need for immediate, accurate, and decentralized testing solutions. Additionally, favorable government initiatives promoting POC testing and the rising number of CLIA-waived tests are enhancing accessibility and adoption across healthcare settings. Together, these factors are accelerating the shift toward faster, patient-centered diagnostics and driving overall market growth.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The point of care diagnostics market is influenced by rising healthcare needs and ongoing innovations in rapid testing technologies. Primary users include hospitals, clinics, ambulatory care facilities, urgent care centers, clinical laboratories, and home-care settings, with applications in disease monitoring, early detection, and routine screening. Trends such as increasing prevalence of chronic and infectious diseases, growing adoption of decentralized testing, technological advancements in immunoassays, molecular diagnostics, and biochemistry platforms, and supportive government initiatives are shaping the development, availability, and adoption of POC solutions. These factors drive investments in diagnostic devices, training, and infrastructure, facilitating wider access and faster decision-making in patient care.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Growing incidence of infectious diseases
-
Increasing prevalence of target conditions
RESTRAINTS
Impact
Level
Level
-
Pricing pressure on manufacturers
-
Stringent regulatory approval process for product commercialization
OPPORTUNITIES
Impact
Level
Level
-
Increasing growth potential in emerging markets
-
Rising inclination toward decentralized healthcare system
CHALLENGES
Impact
Level
Level
-
Inadequate standardization with centralized lab methods
-
Limited awareness in emerging markets
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising number of CLIA-waived POC tests
Rising number of CLIA-waived tests is a key driver of the point of care diagnostics market. The simplicity and standardized nature of these tests allow healthcare providers to perform them in a wide range of settings, including clinics, physician offices, urgent care centers, and even home-care environments, without the need for specialized training or complex laboratory infrastructure. This ease of use enables faster turnaround times and immediate availability of results, which is critical for timely diagnosis, treatment decisions, and patient management. As more diagnostic tests receive CLIA-waived status, their adoption increases, supporting market growth and expanding access to efficient, decentralized testing solutions across diverse healthcare settings.
Restraint: Stringent regulatory approval process for product commercialization
Stringent regulatory approval processes act as a significant restraint on the point of care diagnostics market. Because these products are used directly at the point of care, they must adhere to rigorous safety, accuracy, and performance standards to ensure reliable results for patients. Compliance involves comprehensive testing, clinical trials, detailed documentation, and ongoing audits to satisfy regulatory bodies such as the FDA in the US, CE marking in Europe, and other regional authorities. The process is often time-consuming and complex, which can delay product launches, increase development and operational costs, and limit the ability of smaller or new companies to enter the market. Additionally, frequent updates to regulatory requirements in different regions can further complicate commercialization, requiring continuous monitoring and adaptation by manufacturers to maintain compliance.
Opportunity: Rising inclination toward decentralized healthcare system
As healthcare systems shift toward a more decentralized model, there is a growing trend to expand diagnostic capabilities directly to healthcare providers through point of care testing. This allows for faster clinical decision-making by delivering quick and accurate results, improving patient care and enabling timely interventions. Additionally, decentralization supports early detection and management of infectious and chronic diseases, reducing the burden on centralized laboratories. Consequently, this trend is driving increased demand for POC diagnostic solutions, presenting significant growth opportunities for market players.
Challenge: Inadequate standardization with centralized lab methods
Standardization between point of care testing and centralized laboratory methods is one of the major challenges for wider adoption of point of care diagnostics. Point of care tests may be affected by pre-analytical errors due to improper sampling techniques. POC tests are often performed in emergency or high-pressure situations by nurses or other clinical staff rather than trained laboratory personnel, increasing the likelihood of errors that can impact patient care. Additionally, variations in device calibration, assay performance, and result interpretation across different POC platforms further complicate consistency with centralized laboratory standards, limiting full integration into routine clinical workflows.
Point of Care Diagnostics Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides POC devices for glucose monitoring, infectious disease testing, and cardiometabolic conditions. | Rapid results, user-friendly, supports chronic disease management, enables timely clinical decisions. |
 |
Offers POC platforms for biochemistry, hematology, and infectious disease testing in hospitals and clinics. | Accurate and reliable results, compact and automated systems, improves workflow efficiency, suitable for decentralized care. |
 |
Supplies POC diagnostics for molecular testing, immunoassays, and cardiometabolic monitoring. | High sensitivity and specificity, fast turnaround time, supports early detection, integrates with clinical workflows. |
 |
Provides rapid POC tests for infectious diseases, pregnancy/fertility, and other critical health conditions. | Quick results, easy to use, portable platforms, facilitates early diagnosis and timely intervention. |
 |
Offers POC instruments and assay kits for infectious diseases, glucose monitoring, and biochemistry testing. | Reliable and reproducible results, reduces manual workload, supports decentralized testing, enhances operational efficiency. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The point of care diagnostics market ecosystem comprises device manufacturers, distributors, healthcare providers, clinics, hospitals, and home-care settings working together to deliver rapid and accurate testing. Manufacturers develop solutions for glucose monitoring, infectious disease testing, cardiometabolic monitoring, and other critical health conditions, while distributors ensure timely availability of devices and consumables to healthcare facilities and patients. Primary end users include healthcare professionals, patients, and caregivers, who benefit from quick results, ease of use, and decentralized testing capabilities. Partnerships, regulatory support, and investments in technology are expanding access to POC diagnostics, enabling timely diagnosis, improved patient management, and more efficient healthcare delivery.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Point of Care Diagnostics Market, By Sample
Categorized by sample type, the point of care diagnostics market includes blood samples, urine samples, nasal and oropharyngeal swabs, and other sample types. Blood samples remain a primary choice due to their critical role in detecting a wide range of conditions, including diabetes, cardiovascular diseases, infectious diseases, and metabolic disorders. Blood-based tests are considered accurate, reliable, and capable of delivering rapid results, making them suitable for both clinical and near-patient settings. Technological advancements have further enhanced efficiency, allowing accurate testing with minimal sample volumes. With the continued rise of chronic and infectious diseases, the demand for rapid, convenient, and reliable blood-based diagnostics continues to drive the preference for this sample type.
Point of Care Diagnostics Market, By Product
Based on product, the point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy and fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products. The glucose monitoring products segment dominates the market, primarily due to the growing global burden of diabetes. The increasing number of diabetic patients has led to a consistent need for convenient and accurate glucose monitoring devices for effective disease management. Continuous advancements in technology, along with greater accuracy, user-friendliness, and affordability, have further supported the widespread use of glucose monitoring products among both patients and healthcare professionals.
Point of Care Diagnostics Market, By Mode of Purchase
The point of care diagnostics market, based on mode of purchase, includes over-the-counter (OTC) testing products and prescription-based testing products. Prescription-based testing products dominate this segment due to their widespread use in clinical environments for the accurate diagnosis and management of chronic and infectious diseases. These tests are typically recommended by healthcare professionals to ensure precise detection and appropriate treatment planning. The growing incidence of conditions such as diabetes, cardiovascular diseases, and infections continues to drive the demand for prescription-based testing. Additionally, compliance with stringent clinical standards and regulatory requirements ensures high-quality outcomes, strengthening their adoption across healthcare systems.
Point of Care Diagnostics Market, By Technology
Based on technology, the point of care diagnostics market is segmented into immunoassays, molecular diagnostics, and biochemistry. Biochemistry technology holds a significant position in the market, as it is widely used for testing biochemical markers such as glucose, lipids, and electrolytes, which are essential for managing chronic conditions like diabetes, kidney disease, and cardiovascular disorders. Biochemistry-based point of care devices are preferred for their simplicity, rapid results, and cost-effectiveness, making them suitable for both clinical and home-care environments. Additionally, ongoing miniaturization and technological improvements have enhanced their accuracy and ease of use, further driving their adoption across various healthcare settings.
Point of Care Diagnostics Market, By End User
Based on end user, the point of care diagnostics market includes clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers and urgent care centers, home care settings and self-testing, and other end users. Home care settings and self-testing are increasingly becoming a key focus as patients seek convenience and comfort, allowing them to monitor their health without frequent visits to healthcare facilities. The rapid availability of results, especially for chronic conditions like diabetes, encourages the use of self-testing devices. Technological advancements have improved accuracy, ease of use, and affordability of home-based tests, enabling individuals with minimal training to perform them effectively. With the rise of chronic diseases and a growing emphasis on preventive care and self-management, home care settings and self-testing continue to drive demand in the point of care diagnostics market.
REGION
North America accounted for the largest share of the global point of care diagnostics market during the forecast period.
The point of care diagnostics market in North America is driven by a highly advanced healthcare system, strong infrastructure, and widespread adoption in both clinical and home-care settings. Supportive government initiatives, including funding for healthcare innovations and streamlined regulatory approvals, encourage the development and adoption of new diagnostic technologies. Additionally, robust healthcare research, innovation, and the growing trend of self-testing and at-home healthcare further fuel the demand for point of care diagnostics in the region.
Point of Care Diagnostics Market: COMPANY EVALUATION MATRIX
Abbott is a leading player in the point of care diagnostics market, providing a wide range of testing solutions for chronic diseases, infectious conditions, and cardiometabolic monitoring. Its platforms are designed for rapid, accurate, and user-friendly testing in both clinical and home-care settings. The company focuses on integrating its devices with digital health tools and data management systems, helping healthcare providers make faster decisions, streamline workflows, and improve patient outcomes.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- 1. Abbott (US)
- 2. Siemens Healthineers AG (Germany)
- 3. F. Hoffmann-La Roche Ltd (Switzerland)
- 4. QuidelOrtho Corporation (US)
- 5. Danaher Corporation (US)
- 6. Becton Dickinson and Company (BD) (US)
- 7. Thermo Fisher Scientific Inc. (US)
- 8. bioMérieux (France)
- 9. BIOSYNEX SA (France)
- 10. EKF Diagnostics Holdings plc (UK)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size Value in 2023 | USD 14.26 Billion |
| Revenue Forecast in 2029 | USD 22.63 Billion |
| Growth Rate | CAGR of 8.5% from 2024-2029 |
| Actual data | 2022-2029 |
| Base year | 2023 |
| Forecast period | 2024-2029 |
| Units considered | Value (USD Million), Volume (Million) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By product (glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products), by mode of purchase (OTC testing products and prescription-based testing products), by technology (immunoassays, molecular diagnostics, and biochemistry), by sample (blood samples, urine samples, nasal & oropharyngeal swabs, and other samples), by end user (clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users) |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries |
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | ? Product matrix, which provides a detailed comparison of the product portfolio of each company in the point of care diagnostics market | Enables easy comparison of competitors’ offerings, helping identify gaps, overlaps, and differentiation opportunities. |
| Company Information | ? Additional five company profiles of players operating in the point of care diagnostics market. | Provides insights into competitors’ strategies, innovation focus, and partnerships, supporting strategic planning. |
| Geographic Analysis | ? Additional country-level analysis of the point of care diagnostics market | Guides market entry, localization, and targeted launch strategies by highlighting regional demand and opportunities. |
RECENT DEVELOPMENTS
- June 2024 : bioMérieux (France) received US FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini.
- June 2024 : F. Hoffmann-La Roche Ltd (Switzerland) acquired LumiraDx’s (US) Point of Care technology to further expand its offering in decentralized patient care and drive global access to timely and actionable diagnostic results.
- April 2024 : Abbott’s (US) i-STAT TBI cartridge received clearance from the US FDA to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes.
- December 2023 : Thermo Fisher Scientific Inc. (US) partnered with Project HOPE, an innovative and leading global health and humanitarian organization, to improve the access to Thermo Fisher HIV testing services amongst the HIV positive youth in Sub-Saharan Africa.
- April 2023 : BIOSYNEX SA (France) acquired Chembio Diagnostics, Inc. (US) a leading point of care diagnostics company focused on infectious diseases.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
49
2
RESEARCH METHODOLOGY
55
3
EXECUTIVE SUMMARY
68
4
PREMIUM INSIGHTS
74
5
MARKET OVERVIEW
Emerging markets and decentralized healthcare drive growth amidst pricing and regulatory challenges.
79
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
GROWING INCIDENCE OF INFECTIOUS DISEASES
5.2.1.2
INCREASING PREVALENCE OF CHRONIC DISEASES
5.2.1.3
FAVORABLE GOVERNMENT INITIATIVES FOR POINT OF CARE TESTING
5.2.1.4
RISING NUMBER OF WAIVED TESTS
5.2.2
RESTRAINTS
5.2.2.1
PRICING PRESSURE ON MANUFACTURERS
5.2.2.2
STRINGENT REGULATORY APPROVAL PROCESS FOR PRODUCT COMMERCIALIZATION
5.2.3
OPPORTUNITIES
5.2.3.1
INCREASING GROWTH POTENTIAL IN EMERGING MARKETS
5.2.3.2
RISING INCLINATION TOWARD DECENTRALIZED HEALTHCARE SYSTEM
5.2.3.3
BOOMING HEALTHCARE SPENDING WORLDWIDE
5.2.4
CHALLENGES
5.2.4.1
INADEQUATE STANDARDIZATION WITH CENTRALIZED LAB METHODS
5.2.4.2
PREMIUM PRICING OF NOVEL PLATFORMS
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4
PRICING ANALYSIS
5.4.1
AVERAGE SELLING PRICE, BY PRODUCT
5.4.2
AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
5.4.3
AVERAGE SELLING PRICE, BY REGION
5.4.3.1
AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION
5.4.3.2
AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION
5.4.3.3
AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION
5.5
VALUE CHAIN ANALYSIS
5.6
SUPPLY CHAIN ANALYSIS
5.7
ECOSYSTEM ANALYSIS
5.8
INVESTMENT AND FUNDING SCENARIO
5.9
TECHNOLOGY ANALYSIS
5.9.1
KEY TECHNOLOGIES
5.9.1.1
IMMUNOASSAYS
5.9.2
COMPLEMENTARY TECHNOLOGIES
5.9.2.1
MOLECULAR DIAGNOSTICS
5.9.3
ADJACENT TECHNOLOGIES
5.9.3.1
BIOCHEMICAL TECHNOLOGIES
5.10
PATENT ANALYSIS
5.11
TRADE ANALYSIS
5.11.1
IMPORT DATA FOR HS CODE 3822
5.11.2
EXPORT DATA FOR HS CODE 3822
5.12
KEY CONFERENCES AND EVENTS, 2025–2026
5.13
PORTER’S FIVE FORCES ANALYSIS
5.13.1
BARGAINING POWER OF SUPPLIERS
5.13.2
BARGAINING POWER OF BUYERS
5.13.3
THREAT OF NEW ENTRANTS
5.13.4
THREAT OF SUBSTITUTES
5.13.5
INTENSITY OF COMPETITIVE RIVALRY
5.14
KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2
KEY BUYING CRITERIA
5.15
IMPACT OF AI ON POINT OF CARE DIAGNOSTICS MARKET
5.15.1
INTRODUCTION
5.15.2
MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
5.15.3
AI USE CASES
5.15.4
KEY COMPANIES IMPLEMENTING AI
5.15.5
FUTURE OF AI IN POINT OF CARE DIAGNOSTICS MARKET
5.16
REGULATORY LANDSCAPE
5.16.1
REGULATORY ANALYSIS
5.16.1.1
NORTH AMERICA
5.16.1.2
EUROPE
5.16.1.3
ASIA PACIFIC
5.16.1.4
LATIN AMERICA
5.16.1.5
MIDDLE EAST
5.16.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.17
CASE STUDY ANALYSIS
5.17.1
CASE STUDY 1: IMPACT OF POINT OF CARE PCR TESTING FOR COMMUNITY-ACQUIRED PNEUMONIA IN DENMARK
5.17.2
CASE STUDY 2: ASSESSING POINT OF CARE VIRAL LOAD TESTING IMPACT ON HIV MONITORING IN NIGERIA
5.17.3
CASE STUDY 3: CLINICAL IMPACT OF ROUTINE MOLECULAR POINT OF CARE TEST FOR INFLUENZA IN HOSPITALIZED ADULTS
6
POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2029 in USD Million | 244 Data Tables
126
6.1
INTRODUCTION
6.2
GLUCOSE MONITORING PRODUCTS
6.2.1
GLUCOSE MONITORING STRIPS
6.2.1.1
GROWING TREND TOWARD PREVENTIVE HEALTHCARE TO DRIVE MARKET
6.2.2
GLUCOSE MONITORING METERS
6.2.2.1
GROWING TECHNOLOGICAL ADVANCEMENTS IN GLUCOSE METERS TO PROPEL MARKET
6.2.3
GLUCOSE MONITORING LANCETS & LANCING DEVICES
6.2.3.1
INCREASING TENDENCY FOR HOME-BASED CARE AND SELF-MONITORING TO AID GROWTH
6.3
CARDIOMETABOLIC MONITORING PRODUCTS
6.3.1
CARDIAC MARKER TESTING PRODUCTS
6.3.1.1
GROWING GOVERNMENT SUPPORT FOR CARDIOVASCULAR DISEASES TO DRIVE MARKET
6.3.2
BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
6.3.2.1
NEED TO OPTIMIZE HOSPITAL WORKFLOW TO FAVOR GROWTH
6.3.3
HBA1C TESTING PRODUCTS
6.3.3.1
INCREASING RECOMMENDATIONS BY GOVERNMENT HEALTHCARE AUTHORITIES TO BOOST MARKET
6.4
INFECTIOUS DISEASE TESTING PRODUCTS
6.4.1
RESPIRATORY INFECTION TESTING PRODUCTS
6.4.1.1
INFLUENZA TESTING PRODUCTS
6.4.1.2
TUBERCULOSIS
6.4.1.3
OTHER RESPIRATORY INFECTION TESTING PRODUCTS
6.4.2
HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
6.4.2.1
GROWING RATE OF SURGICAL-SITE INFECTIONS TO BOOST MARKET
6.4.3
TROPICAL DISEASE TESTING PRODUCTS
6.4.3.1
RISING INCIDENCE OF MALARIA AND DENGUE TO SUPPORT GROWTH
6.4.4
SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
6.4.4.1
HIV TESTING PRODUCTS
6.4.4.2
HEPATITIS TESTING PRODUCTS
6.4.4.3
SYPHILIS TESTING PRODUCTS
6.4.4.4
HUMAN PAPILLOMAVIRUS TESTING PRODUCTS
6.4.4.5
CHLAMYDIA TRACHOMATIS TESTING PRODUCTS
6.4.4.6
NEISSERIA GONORRHEA TESTING PRODUCTS
6.4.4.7
HERPES SIMPLEX VIRUS TESTING PRODUCTS
6.4.5
CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
6.4.5.1
RISING CASES AMONG HOSPITALIZED PATIENTS TO BOOST DEMAND
6.4.6
OTHER INFECTIOUS DISEASE TESTING PRODUCTS
6.5
COAGULATION MONITORING PRODUCTS
6.5.1
PT/INR TESTING PRODUCTS
6.5.1.1
INCREASING NUMBER OF ATRIAL FIBRILLATION CASES TO ACCELERATE GROWTH
6.5.2
ACT/APTT TESTING PRODUCTS
6.5.2.1
RISE IN SURGICAL PROCEDURES TO SPEED UP GROWTH
6.6
PREGNANCY & FERTILITY TESTING PRODUCTS
6.6.1
PREGNANCY TESTING PRODUCTS
6.6.1.1
INCREASING AWARENESS ABOUT FAMILY PLANNING TO STIMULATE GROWTH
6.6.2
FERTILITY TESTING PRODUCTS
6.6.2.1
GROWING INFERTILITY ISSUES TO FUEL MARKET
6.7
TUMOR/CANCER MARKER TESTING PRODUCTS
6.7.1
GROWING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET
6.8
URINALYSIS TESTING PRODUCTS
6.8.1
INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO AUGMENT GROWTH
6.9
CHOLESTEROL TESTING PRODUCTS
6.9.1
RISING OBESITY AND CARDIOVASCULAR DISEASES TO FOSTER GROWTH
6.10
HEMATOLOGY TESTING PRODUCTS
6.10.1
INCREASING CASES OF ANEMIA TO SUSTAIN GROWTH
6.11
DRUGS-OF-ABUSE TESTING PRODUCTS
6.11.1
GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
6.12
THYROID-STIMULATING HORMONE TESTING PRODUCTS
6.12.1
RISING PREVALENCE OF THYROID TO ENCOURAGE GROWTH
6.13
FECAL OCCULT TESTING PRODUCTS
6.13.1
GROWING INCIDENCE OF CANCER TO PROPEL MARKET
6.14
OTHER PRODUCTS
7
POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE
Market Size & Growth Rate Forecast Analysis to 2029 in USD Million | 13 Data Tables
246
7.1
INTRODUCTION
7.2
PRESCRIPTION-BASED TESTING PRODUCTS
7.2.1
RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
7.3
OTC TESTING PRODUCTS
7.3.1
GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
8
POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2029 in USD Million | 31 Data Tables
255
8.1
INTRODUCTION
8.2
BIOCHEMISTRY
8.2.1
INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
8.3
IMMUNOASSAYS
8.3.1
GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
8.4
MOLECULAR DIAGNOSTICS
8.4.1
RT-PCR
8.4.1.1
GROWING USE OF RT-PCR IN PROTEOMICS AND GENOMICS TO BOOST MARKET
8.4.2
INAAT
8.4.2.1
EMERGING NEW PATHOGENS TO FACILITATE GROWTH
9
POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE
Market Size & Growth Rate Forecast Analysis to 2029 in USD Million | 25 Data Tables
273
9.1
INTRODUCTION
9.2
BLOOD SAMPLES
9.2.1
GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
9.3
NASAL & OROPHARYNGEAL SWABS
9.3.1
INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
9.4
URINE SAMPLES
9.4.1
NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
9.5
OTHER SAMPLES
10
POINT OF CARE DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2029 in USD Million | 26 Data Tables
289
10.1
INTRODUCTION
10.2
HOME CARE SETTINGS AND SELF-TESTING
10.2.1
INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
10.3
CLINICAL LABORATORIES
10.3.1
GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
10.4
HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
10.4.1
RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
10.5
AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES
10.5.1
NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
10.6
OTHER END USERS
11
POINT OF CARE DIAGNOSTICS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 14 Countries | 334 Data Tables.
305
11.1
INTRODUCTION
11.2
NORTH AMERICA
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2
US
11.2.2.1
PRESENCE OF ADVANCED HEALTHCARE INFRASTRUCTURE AND HIGH HEALTHCARE EXPENDITURES TO AID GROWTH
11.2.3
CANADA
11.2.3.1
RISING INCIDENCE OF DIABETES AND INFECTIOUS DISEASES TO SUPPORT GROWTH
11.3
EUROPE
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2
GERMANY
11.3.2.1
INCREASING NEED FOR RAPID AND ACCURATE DIAGNOSTIC SOLUTIONS TO PROMOTE GROWTH
11.3.3
FRANCE
11.3.3.1
GROWING DEMAND FOR ACCESSIBLE AND CONVENIENT DIAGNOSTIC TOOLS TO PROPEL MARKET
11.3.4
UK
11.3.4.1
RISING NUMBER OF ACCREDITED CLINICAL AND HOSPITAL LABORATORIES TO SUSTAIN GROWTH
11.3.5
ITALY
11.3.5.1
GROWING BURDEN OF INFECTIOUS AND PARASITIC DISEASES TO BOOST MARKET
11.3.6
SPAIN
11.3.6.1
RISING PREVALENCE OF CIRCULATORY SYSTEM DISEASES TO CONTRIBUTE TO GROWTH
11.3.7
REST OF EUROPE
11.4
ASIA PACIFIC
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2
CHINA
11.4.2.1
INCREASING IMPACT OF DIABETES ON PUBLIC HEALTH TO AMPLIFY GROWTH
11.4.3
JAPAN
11.4.3.1
BOOMING GERIATRIC POPULATION TO STIMULATE GROWTH
11.4.4
INDIA
11.4.4.1
INCREASING CASES OF CHRONIC HEART AND KIDNEY DISEASES TO FOSTER GROWTH
11.4.5
AUSTRALIA
11.4.5.1
GROWING RESEARCH INVESTMENTS FOR NEXT-GEN POINT OF CARE DEVICES TO BOOST MARKET
11.4.6
SOUTH KOREA
11.4.6.1
GROWING FOCUS ON INNOVATIVE DIAGNOSTIC PRODUCTS TO DRIVE MARKET
11.4.7
REST OF ASIA PACIFIC
11.5
LATIN AMERICA
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2
BRAZIL
11.5.2.1
INCREASING PUBLIC INITIATIVES IN HEALTHCARE TO ENCOURAGE GROWTH
11.5.3
MEXICO
11.5.3.1
NEED FOR FREQUENT TESTING FOR DISEASE MANAGEMENT TO EXPEDITE GROWTH
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST & AFRICA
11.6.1
GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
11.6.2
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.7
GCC COUNTRIES
11.7.1
BOOMING HEALTHCARE INFRASTRUCTURE TO FACILITATE GROWTH
11.7.2
MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
12
COMPETITIVE LANDSCAPE
Uncover top strategies and market shares driving key players in point-of-care diagnostics.
473
12.1
INTRODUCTION
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
12.3
REVENUE ANALYSIS, 2021–2023
12.4
MARKET SHARE ANALYSIS, 2023
12.5
COMPANY VALUATION AND FINANCIAL METRICS
12.6
BRAND/PRODUCT COMPARISON
12.6.1
ABBOTT
12.6.2
F. HOFFMANN-LA ROCHE LTD.
12.6.3
NOVA BIOMEDICAL
12.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.7.1
STARS
12.7.2
EMERGING LEADERS
12.7.3
PERVASIVE PLAYERS
12.7.4
PARTICIPANTS
12.7.5
COMPANY FOOTPRINT, KEY PLAYERS, 2023
12.7.5.1
COMPANY FOOTPRINT
12.7.5.2
REGION FOOTPRINT
12.7.5.3
MODE OF PURCHASE FOOTPRINT
12.7.5.4
TECHNOLOGY FOOTPRINT
12.7.5.5
SAMPLE FOOTPRINT
12.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.8.1
PROGRESSIVE COMPANIES
12.8.2
RESPONSIVE COMPANIES
12.8.3
DYNAMIC COMPANIES
12.8.4
STARTING BLOCKS
12.9
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.9.1
DETAILED LIST OF KEY STARTUPS/SMES
12.9.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
12.10
COMPETITIVE SCENARIO
12.10.1
PRODUCT LAUNCHES AND APPROVALS
12.10.2
DEALS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
493
13.1
KEY PLAYERS
13.1.1
ABBOTT
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
PRODUCTS OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.1.4
MNM VIEW
13.1.2
SIEMENS HEALTHINEERS AG
13.1.3
F. HOFFMANN-LA ROCHE LTD
13.1.4
DANAHER
13.1.5
QUIDELORTHO CORPORATION
13.1.6
BD
13.1.7
THERMO FISHER SCIENTIFIC INC.
13.1.8
BIOMÉRIEUX
13.1.9
BIOSYNEX SA
13.1.10
EKF DIAGNOSTICS HOLDINGS PLC
13.1.11
TRINITY BIOTECH
13.1.12
WERFEN
13.1.13
NOVA BIOMEDICAL
13.1.14
SEKISUI DIAGNOSTICS
13.1.15
BODITECH MED INC.
13.2
OTHER PLAYERS
13.2.1
GRIFOLS, S.A.
13.2.2
LIFESCAN IP HOLDINGS, LLC
13.2.3
PTS DIAGNOSTICS
13.2.4
EUROLYSER DIAGNOSTICA GMBH
13.2.5
RESPONSE BIOMEDICAL
13.2.6
ALFA SCIENTIFIC DESIGNS, INC.
13.2.7
BTNX INC.
13.2.8
ASCENSIA DIABETES CARE HOLDINGS AG
13.2.9
FLUXERGY
13.2.10
PRECISION BIOSENSOR, INC.
13.2.11
ACON LABORATORIES, INC.
13.2.12
MENARINI DIAGNOSTICS S.R.L
13.2.13
ORASURE TECHNOLOGIES, INC.
13.2.14
MANKIND PHARMA
14
APPENDIX
568
14.1
DISCUSSION GUIDE
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
14.4
RELATED REPORTS
14.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
POINT OF CARE DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3
POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT
TABLE 4
PROJECTED INCREASE OF CANCER PATIENTS, BY REGION, 2022 VS. 2035 VS. 2045
TABLE 5
GLOBAL DIABETES ESTIMATES (AGES 20–79) BY REGION, 2021 VS. 2030 VS. 2045 (IN THOUSANDS)
TABLE 6
PRODUCT WAIVERS, BY KEY PLAYER, 2021–2024
TABLE 7
AVERAGE SELLING PRICE OF POINT OF CARE TESTS, BY PRODUCT, 2022–2024
TABLE 8
AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2022–2024
TABLE 9
AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2022–2024
TABLE 10
AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2024
TABLE 11
AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022–2024
TABLE 12
POINT OF CARE DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 13
POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022–2023
TABLE 14
IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)
TABLE 15
EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)
TABLE 16
POINT OF CARE DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 17
POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 18
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
TABLE 19
KEY BUYING CRITERIA, BY TECHNOLOGY
TABLE 20
EUROPE: CLASSIFICATION OF IVD DEVICES
TABLE 21
CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 22
JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 23
AUSTRALIA: CLASSIFICATION OF IVD MEDICAL DEVICES
TABLE 24
NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25
EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26
ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 28
REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29
POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 30
DIABETES-RELATED HEALTH EXPENDITURE PER PERSON, 2021 VS. 2030 VS. 2045 (USD)
TABLE 31
POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 32
POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 33
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 34
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 35
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 36
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 37
KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE
TABLE 38
POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY REGION, 2022–2029 (USD MILLION)
TABLE 39
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43
KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE
TABLE 44
POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 45
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 46
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 47
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49
KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE
TABLE 50
POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 51
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55
KEY CARDIOMETABOLIC MONITORING PRODUCTS AVAILABLE WORLDWIDE
TABLE 56
POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 57
POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 58
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62
POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 63
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 64
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67
POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 68
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 72
POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 73
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 77
POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 78
POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 79
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 80
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 82
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83
POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 84
POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 85
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 87
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89
KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 90
POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 91
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 93
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 94
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95
KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 96
POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 97
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 99
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 100
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101
OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 102
POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 103
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 105
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107
KEY HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 108
POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 109
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 110
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 111
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113
KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 114
POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 115
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 117
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119
POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 120
POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 121
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 122
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125
KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 126
POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 127
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 129
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131
POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 132
POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 133
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 135
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 136
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137
KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 138
POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 139
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 140
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 141
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143
KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 144
POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 145
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 146
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 147
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149
KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 150
POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 151
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 152
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 154
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 155
KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 156
POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 157
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 159
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 161
KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 162
POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 163
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 164
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 165
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 166
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 167
POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 168
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 169
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 170
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 171
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 172
KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 173
POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 174
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 175
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 176
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 177
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 178
KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 179
POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 180
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 182
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 183
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 184
OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 185
POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 186
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 187
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 188
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 189
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190
KEY COAGULATION MONITORING PRODUCTS AVAILABLE WORLDWIDE
TABLE 191
POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 192
POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 193
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 194
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 195
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 196
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 197
POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 198
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 199
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 200
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 201
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 202
POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 203
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 204
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 205
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 206
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 207
POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208
POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 209
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 210
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 211
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 212
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 213
KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 214
POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 215
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 216
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 217
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 218
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 219
KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 220
POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 221
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 222
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 223
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 224
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 225
TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045
TABLE 226
KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 227
POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 228
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 229
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 230
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 231
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 232
KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 233
POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 234
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 235
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 236
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 237
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 238
KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 239
POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 240
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 241
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 242
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 243
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 244
KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 245
POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 246
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 247
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 248
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 249
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 250
KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 251
POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 252
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 253
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 254
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 255
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 256
POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 257
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 258
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 259
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 260
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 261
KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 262
POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 263
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 264
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 265
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 266
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 267
KEY OTHER POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 268
POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 269
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 270
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 271
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 272
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 273
POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 274
KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 275
POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 276
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 277
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 278
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 279
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 280
KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 281
POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 282
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 283
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 284
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 285
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 286
POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 287
KEY BIOCHEMISTRY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 288
POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2022–2029 (USD MILLION)
TABLE 289
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 290
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 291
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 292
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 293
KEY IMMUNOASSAY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 294
POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION)
TABLE 295
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 296
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 297
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 298
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 299
POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 300
POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 301
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 302
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 303
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 304
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 305
KEY RT-PCR-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 306
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2022–2029 (USD MILLION)
TABLE 307
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 308
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 309
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 310
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 311
KEY INAAT-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 312
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2022–2029 (USD MILLION)
TABLE 313
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 314
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 315
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 316
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 317
POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 318
KEY BLOOD SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 319
POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION)
TABLE 320
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 321
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 322
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 323
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 324
KEY NASAL AND OROPHARYNGEAL SWAB-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 325
POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2022–2029 (USD MILLION)
TABLE 326
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 327
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 328
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 329
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 330
KEY URINE SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 331
POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2022–2029 (USD MILLION)
TABLE 332
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 333
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 334
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 335
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 336
KEY OTHER SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 337
POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022–2029 (USD MILLION)
TABLE 338
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 339
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 340
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 341
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 342
POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 343
POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2022–2029 (USD MILLION)
TABLE 344
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 345
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 346
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 347
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 348
POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 349
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 350
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 351
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 352
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 353
POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 354
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 355
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 356
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 357
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 358
POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 359
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 360
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 361
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 362
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 363
POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 364
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 365
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 366
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 367
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 368
POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 369
NORTH AMERICA: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET
TABLE 370
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 371
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 372
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 373
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 374
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 375
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 376
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 377
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 378
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 379
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 380
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 381
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 382
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 383
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 384
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 385
NORTH AMERICA: NUMBER OF WOMEN USING HOME PREGNANCY KITS, BY COUNTRY, 2022–2029 (MILLION UNIT)
TABLE 386
US: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 387
US: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 388
US: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 389
US: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 390
US: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 391
US: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 392
US: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 393
US: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 394
US: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 395
US: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 396
US: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 397
US: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 398
US: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 399
US: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 400
CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 401
CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 402
CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 403
CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 404
CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 405
CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 406
CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 407
CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 408
CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 409
CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 410
CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 411
CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 412
CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 413
CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 414
MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET IN EUROPE
TABLE 415
EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 416
EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 417
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 418
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 419
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 420
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 421
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 422
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 423
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 424
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 425
EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 426
EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 427
EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 428
EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 429
EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 430
GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 431
GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 432
GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 433
GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 434
GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 435
GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 436
GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 437
GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 438
GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 439
GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 440
GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 441
GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 442
GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 443
GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 444
FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 445
FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 446
FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 447
FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 448
FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 449
FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 450
FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 451
FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 452
FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 453
FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 454
FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 455
FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 456
FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 457
FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 458
UK: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 459
UK: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 460
UK: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 461
UK: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 462
UK: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 463
UK: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 464
UK: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 465
UK: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 466
UK: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 467
UK: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 468
UK: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 469
UK: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 470
UK: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 471
UK: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 472
ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 473
ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 474
ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 475
ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 476
ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 477
ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 478
ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 479
ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 480
ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 481
ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 482
ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 483
ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 484
ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 485
ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 486
SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 487
SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 488
SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 489
SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 490
SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 491
SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 492
SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 493
SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 494
SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 495
SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 496
SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 497
SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 498
SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 499
SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 500
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 501
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 502
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 503
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 504
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 505
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 506
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 507
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 508
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 509
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 510
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 511
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 512
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 513
REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 514
ASIA PACIFIC: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET
TABLE 515
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 516
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 517
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 518
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 519
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 520
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 521
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 522
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 523
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 524
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 525
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 526
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 527
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 528
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 529
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 530
CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 531
CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 532
CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 533
CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 534
CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 535
CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 536
CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 537
CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 538
CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 539
CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 540
CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 541
CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 542
CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 543
CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 544
JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 545
JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 546
JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 547
JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 548
JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 549
JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 550
JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 551
JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 552
JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 553
JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 554
JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 555
JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 556
JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 557
JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 558
INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 559
INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 560
INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 561
INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 562
INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 563
INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 564
INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 565
INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 566
INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 567
INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 568
INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 569
INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 570
INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 571
INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 572
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 573
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 574
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 575
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 576
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 577
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 578
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 579
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 580
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 581
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 582
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 583
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 584
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 585
AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 586
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 587
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 588
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 589
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 590
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 591
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 592
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 593
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 594
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 595
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 596
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 597
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 598
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 599
SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 600
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 601
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 602
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 603
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 604
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 605
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2 022–2029 (USD MILLION)
TABLE 606
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 607
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 608
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 609
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 610
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 611
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 612
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 613
REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 614
MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET IN LATIN AMERICA
TABLE 615
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 616
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 617
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 618
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 619
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 620
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 621
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 622
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 623
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 624
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 625
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 626
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 627
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 628
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 629
LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 630
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 631
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 632
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 633
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 634
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 635
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 636
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 637
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 638
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 639
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 640
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 641
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 642
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 643
BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 644
MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 645
MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 646
MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 647
MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 648
MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 649
MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 650
MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 651
MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 652
MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 653
MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 654
MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 655
MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 656
MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 657
MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 658
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 659
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 660
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 661
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 662
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 663
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 664
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 665
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 666
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 667
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 668
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 669
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 670
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 671
REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 672
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 673
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 674
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 675
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 676
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 677
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 678
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 679
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 680
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 681
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 682
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 683
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 684
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 685
MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 686
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 687
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 688
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 689
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 690
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 691
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 692
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 693
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 694
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 695
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 696
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
TABLE 697
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 698
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 699
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
TABLE 700
GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 701
GCC COUNTRIES: MACROECONOMIC INDICATORS
TABLE 702
OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN POINT OF CARE DIAGNOSTICS MARKET, JANUARY 2021–NOVEMBER 2024
TABLE 703
POINT OF CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
TABLE 704
POINT OF CARE DIAGNOSTICS MARKET: REGION FOOTPRINT
TABLE 705
POINT OF CARE DIAGNOSTICS MARKET: MODE OF PURCHASE FOOTPRINT
TABLE 706
POINT OF CARE DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
TABLE 707
POINT OF CARE DIAGNOSTICS MARKET: SAMPLE FOOTPRINT
TABLE 708
POINT OF CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 709
POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
TABLE 710
POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
TABLE 711
POINT OF CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 712
POINT OF CARE DIAGNOSTICS MARKET: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 713
ABBOTT: COMPANY OVERVIEW
TABLE 714
ABBOTT: PRODUCTS OFFERED
TABLE 715
ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 716
ABBOTT: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 717
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 718
SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
TABLE 719
SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 720
SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 721
SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
TABLE 722
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 723
F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 724
F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 725
F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 726
F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
TABLE 727
DANAHER: COMPANY OVERVIEW
TABLE 728
DANAHER: PRODUCTS OFFERED
TABLE 729
DANAHER: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 730
QUIDELORTHO CORPORATION: COMPANY OVERVIEW
TABLE 731
QUIDELORTHO CORPORATION: PRODUCTS OFFERED
TABLE 732
QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 733
QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 734
QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
TABLE 735
BD: COMPANY OVERVIEW
TABLE 736
BD: PRODUCTS OFFERED
TABLE 737
BD: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 738
BD: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
TABLE 739
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 740
THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 741
THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 742
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 743
BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 744
BIOMÉRIEUX: PRODUCTS OFFERED
TABLE 745
BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 746
BIOMÉRIEUX: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 747
BIOSYNEX SA: COMPANY OVERVIEW
TABLE 748
BIOSYNEX SA: PRODUCTS OFFERED
TABLE 749
BIOSYNEX SA: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 750
EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
TABLE 751
EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
TABLE 752
EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 753
EKF DIAGNOSTICS HOLDINGS PLC: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 754
EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
TABLE 755
TRINITY BIOTECH: COMPANY OVERVIEW
TABLE 756
TRINITY BIOTECH: PRODUCTS OFFERED
TABLE 757
TRINITY BIOTECH: PRODUCT APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 758
TRINITY BIOTECH: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 759
WERFEN: COMPANY OVERVIEW
TABLE 760
WERFEN: PRODUCTS OFFERED
TABLE 761
WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 762
WERFEN: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 763
NOVA BIOMEDICAL: COMPANY OVERVIEW
TABLE 764
NOVA BIOMEDICAL: PRODUCTS OFFERED
TABLE 765
NOVA BIOMEDICAL: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 766
NOVA BIOMEDICAL: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
TABLE 767
SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
TABLE 768
SEKISUI DIAGNOSTICS: PRODUCTS OFFERED
TABLE 769
BODITECH MED INC.: COMPANY OVERVIEW
TABLE 770
BODITECH MED INC.: PRODUCTS OFFERED
TABLE 771
BODITECH MED INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
TABLE 772
BODITECH MED INC.: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 773
BODITECH MED INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
TABLE 774
GRIFOLS, S.A.: COMPANY OVERVIEW
TABLE 775
LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW
TABLE 776
PTS DIAGNOSTICS : COMPANY OVERVIEW
TABLE 777
EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW
TABLE 778
RESPONSE BIOMEDICAL: COMPANY OVERVIEW
TABLE 779
ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW
TABLE 780
BTNX INC.: COMPANY OVERVIEW
TABLE 781
ASCENSIA DIABETES CARE HOLDINGS AG: COMPANY OVERVIEW
TABLE 782
FLUXERGY: COMPANY OVERVIEW
TABLE 783
PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW
TABLE 784
ACON LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 785
MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW
TABLE 786
ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 787
MANKIND PHARMA: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
POINT OF CARE DIAGNOSTICS MARKET SEGMENTATION AND REGIONS COVERED
FIGURE 2
POINT OF CARE DIAGNOSTICS MARKET: RESEARCH DESIGN
FIGURE 3
POINT OF CARE DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS
FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 5
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 6
BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 7
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 8
POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
FIGURE 9
POINT OF CARE DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY
FIGURE 10
POINT OF CARE DIAGNOSTICS MARKET: PARAMETRIC ASSUMPTIONS
FIGURE 11
POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 12
POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029 (USD MILLION)
FIGURE 13
POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 14
POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029 (USD MILLION)
FIGURE 15
POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 16
POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
FIGURE 17
RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
FIGURE 18
GLUCOSE MONITORING PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 19
PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 20
BIOCHEMISTRY SEGMENT TO WITNESS LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 21
BLOOD SAMPLES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 22
HOME CARE SETTINGS AND SELF-TESTING SEGMENT TO HOLD LARGEST MARKET SHARE IN 2029
FIGURE 23
ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 24
POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25
REGIONAL INCIDENCE OF HIV, 2023
FIGURE 26
NEW REVENUE POCKETS FOR PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
FIGURE 27
POINT OF CARE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 28
POINT OF CARE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 29
POINT OF CARE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 30
INVESTMENT AND FUNDING SCENARIO, 2021–2024
FIGURE 31
POINT OF CARE DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2023
FIGURE 32
POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 33
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY
FIGURE 34
KEY BUYING CRITERIA, BY TECHNOLOGY
FIGURE 35
MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
FIGURE 36
US: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 37
CANADA: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 38
JAPAN: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 39
INDIA: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 40
BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 41
PREVALENCE OF DIABETES IN IDF REGIONS AMONG 20–79 YEARS OF ADULTS, 2021 VS. 2045 (%)
FIGURE 42
PREVALENCE OF HEART AND CIRCULATORY DISEASE WORLDWIDE, 2021 (MILLION)
FIGURE 43
NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 44
ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 45
REVENUE ANALYSIS OF KEY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET 2021–2023
FIGURE 46
MARKET SHARE ANALYSIS OF KEY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET, 2023
FIGURE 47
EV/EBITDA OF KEY VENDORS, 2024
FIGURE 48
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
FIGURE 49
POINT OF CARE DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
FIGURE 50
POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 51
POINT OF CARE DIAGNOSTICS MARKET: COMPANY FOOTPRINT
FIGURE 52
POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 53
ABBOTT: COMPANY SNAPSHOT (2023)
FIGURE 54
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
FIGURE 55
F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
FIGURE 56
DANAHER: COMPANY SNAPSHOT (2023)
FIGURE 57
QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)
FIGURE 58
BD: COMPANY SNAPSHOT (2023)
FIGURE 59
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
FIGURE 60
BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
FIGURE 61
BIOSYNEX SA: COMPANY SNAPSHOT (2023)
FIGURE 62
EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2023)
FIGURE 63
TRINITY BIOTECH: COMPANY SNAPSHOT (2023)
FIGURE 64
WERFEN: COMPANY SNAPSHOT (2023)
Methodology
The study involved major activities in estimating the current market size for the point of care diagnostics market. Exhaustive secondary research was done to collect information on the point of care diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the point of care diagnostics market.
The four steps involved in estimating the market size are
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| Abbott | Regional Sales Manager |
| F. Hoffmann-La Roche Ltd | Product Manager |
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the point of care diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the point of care diagnostics market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Point of care testing (POCT) includes screening or diagnostic tests that are designed to be used at or near the patient's site (such as at home, in an ambulance, at a physician's office, and other locations). POCT allows rapid and reliable diagnostic testing to obtain outcomes instantly, helping physicians/patients make care decisions remotely and as soon as possible.
Stakeholders
- Senior Management
- End User
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global point of care diagnostics market, by product, mode of purchase, technology, sample, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall point of care diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Latin America, Middle East & Africa, and GCC countries
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Key Questions Addressed by the Report
What are the recent trends affecting the point of care diagnostics market?
Recent trends in the point of care diagnostics market include significant technological advancements, rising demand for fast and accurate testing, and the shift towards patient-centered care. The government funding in POC test development and adoption is also picking up, including investments in research, innovation, and infrastructure for new product development, increased accessibility, and reduced costs of testing.
What are the major sample types for point of care diagnostic tests?
Based on sample, the point of care diagnostics market can broadly be divided into blood samples, urine samples, nasal & oropharyngeal swabs, and other samples. Blood samples have dominated the point of care diagnostics market because of their ease of collection, accuracy, and advancements in minimally invasive collection methods such as fingerstick and micro-sampling techniques.
Who are the key players in the point of care diagnostics market?
The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), and Boditech Med Inc. (South Korea).
Who are the major end users of point of care diagnostic products?
The point of care diagnostics market is bifurcated into clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users, based on end user. Home care settings and self-testing account for the largest end user segment in the point of care diagnostics market, which is driven by a growing need for convenient, cost-effective, and personalized healthcare solutions.
Which region is lucrative for the point of care diagnostics market?
The Asia Pacific region is one of the most promising regions in the point of care diagnostics market, primarily due to its expanding healthcare infrastructure, increased healthcare expenditure, government initiatives for improving access to healthcare, and awareness of early diagnosis benefits.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Point of Care Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Before You Go
Expand Beyond Point of Care Diagnostics Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Growth opportunities and latent adjacency in Point of Care Diagnostics Market